OBJECTIVES No national registries for chronic lymphocytic leukaemia (CLL) exist in Germany. The objective of this analysis was to examine the number of patients with CLL diagnosed (with or without other diagnoses of cancer) and to characterize the types of treatment being utilized and care settings using sickness funds claim data. METHODS This analysis evaluates data from 1,771,225 beneficiaries in 2012 from different statutory sickness funds. Patients with CLL were identified by ICD-10 C91.1*, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemotherapy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number (PZN) 9999092 and/or operating and procedure code (OPS) 854*.  RESULTS In total, 1,405 patients with a diagnosis C91.1* (CLL) were identified (prevalence 79/100,000) with 60.2% were male and 39.8% female. Overall, 32.2% of patients with CLL had a co-diagnosis with another cancer; 25.1% melanoma (C43-44), 21.3% had neoplasms with unknown behaviour (D37-48), 11.8% had malignant male GU neoplasms (90% prostate cancer) (C60-63), 10.7% had malignant neoplasms of digestive organs (C15-26) and 8,4% showed malignant neoplasms of ill-defined, secondary and unspecified sites (C76-80). The outpatient diagnosis rate for CLL was 94.9%, inpatient rate 0.6% and in-and outpatient rate 4.6%. Overall, 266 of 1,405 pts (18.9%) (175 men [65.8%], 91 women [34.2%]) received chemotherapy in 2012 (ATC Code L01* 74.1%, PZN 9999092 23.0%, OPS 854* 2.9%). Most patients received outpatient treatment (94.0%), with 5.3% of patients received both out- and inpatient treatment and 0.7% inpatient treatment. The most commonly used treatments were rituximab (26.7%), bendamustine (20.2%), chlorambucil (11.1%), cyclophosphamide (7.7%), fludarabine (6.2%) and other treatments (28.1%). CONCLUSIONS The majority of patients being diagnosed with CLL did not require treatment within a time period of a year. Approximately 1/3 of patients had a second malignancy, predominantly skin cancer. Treatment was primarily composed of chemotherapy or chemoimmunotherapy.